Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥587.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)121.17K
Market Cap
¥11.64B
Enterprise Value¥12.28K
Total Cash (Recent Filing)¥3.96B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.81
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)46.6
Revenue Forecast (FY)¥2.20B
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt and roughly ¥4.37B of equity give SUSMED durable financial flexibility and lower solvency risk. With no interest burden the company can prioritize product investment or absorb losses during a multi-quarter turnaround, extending runway before financing becomes urgent.
High Gross MarginsExtremely high gross margins (~97%) indicate strong unit economics and possible pricing power from its technology-enabled services. If the company scales revenue while controlling operating costs, those margins can translate into rapid operating leverage and sustainable profitability over time.
Revenue RecoveryResumption of top-line growth (+2.33% in 2025) signals improving market traction after a prior decline. Sustained revenue recovery is a necessary precursor to fixed-cost absorption and margin expansion, suggesting product-market fit improvements that could underpin durable scale if maintained.
Bears Say
Deep UnprofitabilityA ~-64% net margin reflects structural inability to convert high gross margins into profit due to high operating costs or SG&A. Persistent large net losses erode shareholder value and require sustained revenue growth or material cost restructuring to reach long-term viability.
Worsening Cash BurnOperating and free cash flow deepened to roughly -¥432M/-¥437M in 2025 and worsened year-over-year, creating a durable liquidity pressure. Even with no debt, sustained negative cash conversion forces capital raises or asset sales, diluting equity or constraining strategic investments.
Equity Erosion & Negative ROEEquity erosion and a negative ROE (~-6.8%) through 2025 indicate the company is destroying shareholder value. Over months this weakens the capital base, reduces financial flexibility relative to peers, and raises the likelihood of external financing under unfavorable terms if losses persist.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥587.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥11.64B.
When is SUSMED,Inc.’s upcoming earnings report date?
SUSMED,Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 16 days.
How were SUSMED,Inc.’s earnings last quarter?
SUSMED,Inc. released its earnings results on May 08, 2026. The company reported -¥3.54 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
SUSMED,Inc. reported an EPS of -¥3.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.611%.
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.